[Changes in renal function on response to rapid administration of cisplatinum]

Area of Science:

• Nephrology
• Oncology
• Pharmacology

Context:

• Urologic carcinomas present significant treatment challenges.
• Cisplatin (CDDP) is a cornerstone chemotherapy agent but can cause nephrotoxicity.
• Optimizing CDDP administration is crucial for patient outcomes and treatment accessibility.

Purpose:

• To evaluate the renal function changes in patients with urologic carcinomas receiving high-rate Cisplatin (CDDP) infusion.
• To compare the safety profile of rapid CDDP administration with traditional prolonged infusion methods regarding nephrotoxicity.

Summary:

• Seven patients with urologic carcinomas received high-rate Cisplatin (CDDP) (50-100 mg/m2 within 5 hours) with aggressive hydration.
• Transient elevations in Blood Urea Nitrogen (BUN) and serum creatinine, along with decreased creatinine clearance (Ccr), were observed in some patients.
• These renal function impairments were reversible and did not necessitate treatment discontinuation, indicating a favorable safety profile.

Impact:

• Rapid Cisplatin (CDDP) infusion is a safe alternative to prolonged infusion, with manageable and reversible renal effects.
• This administration method could facilitate outpatient Cisplatin (CDDP) chemotherapy, improving patient convenience and potentially reducing healthcare costs.
• The findings support the feasibility of outpatient Cisplatin (CDDP) treatment for urologic carcinomas.